ABSTRACT
Background: Dihydroartemisinin 40mg and piperaquine phosphate 320mg (DHA-PQP) drug combination and piperaquin phosphate (PQP) material was first successfully produced in Vietnam \r\n', u'Objective: to study influences of the fixed combination antimalaria drug dihydroartemisinin plus piperaquine in reproductive progress of mice\r\n', u"Subjects and methods: This study was carried out at the Department of Malaria treatment and research, National Institute of Malariology, Parasitology and Entomology (NIMPE), between September, 2006 and March, 2007. The influences of the fixed combination antimalarial drug 40 mg dihydroartemisinin (DHA) plus 320 mg piperaquine phosphate (PQP), with PQP produced firstly in Vietnam, in mice's reproductive progresses were investigated in three generations (including the parent and FI, F2 child generations). \r\n", u'Results: In all three generations, study indices among the treated and control groups were not significantly different (the values P > 0.05). These indices included the rate of fecundation, numbers of fetuses of each mother mouse, numbers of offspring of each mother mouse, mean body weights of offspring. Early lethal fetuses, lately lethal fetuses, monsters and innate abnormally offspring were not found in P, FI and F2 generations. The necessary feeding - day numbers that offspring of P and F 1 generations reached their body weights about 20g were different insignificantly (the values P> 0.05) among the treated and control groups. \r\n', u'Conclusion: The combination DHA-PQP was found to cause no genome mutations in mice at the oral dose of 120 mg per kg per day for 5 consecutive days. \r\n', u'